AnalyzeDirect O’Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. June 2004;62(11):2038-2043.
Publication Date
June 2004
How Analyze was Used
“Volume analysis of Gd-enhancing lesions was performed in a similar sequence-blinded manner by the same technician for the entire study, using software (Analyze AVW …) that makes use of voxel intensity thresholding to outline lesions.”
Keywords
Acute Disease
Adult
Antibodies, Monoclonal/adverse effects/therapeutic use
Antibodies, Monoclonal, Humanized
Blood-Brain Barrier
Brain/drug effects/pathology
Chemotaxis, Leukocyte/drug effects
Contrast Media
Double-Blind Method
Female
Gadolinium/diagnostic use
Humans
Integrin alpha4/immunology
Magnetic Resonance Imaging (MRI)
Male
Multiple Sclerosis, Relapsing-Remitting/drug therapy/pathology
Severity of Illness Index
Treatment Outcome
Author Affiliation(s)
St. Michael’s Hospital, Toronto, Ontario, Canada. (LM)
Clinical Neurosciences, Foothills Hospital, Calgary, Alberta, Canada. (PWO)
Department of Neurology, University of Rochester Medical Center, Rochester, NY, US. (AG)
Elan Pharmaceuticals, Inc., San Diego, CA, US. (AJWH, MAL)
Rocky Mountain MS Center, Englewood, CO, US. (RSM)
Department of Neurology, University of Miami School of Medicine, FL, US. (WAS)
Division of Neurology, Barrow Neurological Institute, Phoenix, AZ, US. (TLV)
Mellen Center for MS Research and Treatment, Department of Neurology, Cleveland Clinic Foundation, Cleveland, OH, US. (LAS)
ID# 2356
Tags: Acute Disease, Adult, Blood-Brain Barrier, Brain/drug effects/pathology, Contrast Media, Double-Blind Method, Female, Gadolinium/diagnostic use, Humans, Integrin alpha4/immunology, Leukocyte Chemotaxis/drug effects, Magnetic Resonance Imaging (MRI), Male, Monoclonal Antibodies_Humanized, Monoclonal Antibodies/adverse effects/therapeutic use, Relapsing-Remitting Multiple Sclerosis/drug therapy/pathology, Severity of Illness Index, Treatment Outcome